Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

Oncotarget

Volumn 8, Issue 11, 2017, Pages 18359-18372

  Hu, Chen ^a,b   Wang, Aoli ^a,b   Wu, Hong ^a,c   Qi, Ziping ^a,c   Li, Xixiang ^a,c   Yan, Xiao E ^d   Chen, Cheng ^a,b   Yu, Kailin ^a,b   Zou, Fengming ^a,c   Wang, Wenchao ^a,c   Wang, Wei ^a,c   Wu, Jiaxin ^a,b   Liu, Juan ^a,b   Wang, Beilei ^a,b   Wang, Li ^a,b   Ren, Tao ^e   Zhang, Shanchun ^c,f   Yun, Cai Hong ^d   Liu, Jing ^a,c   Liu, Qingsong ^a,b,c,e  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c CHMFL HCMTC Target Therapy Joint Laboratory   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e HEFEI INSTITUTES OF PHYSICAL SCIENCE   (China)

^f Hefei Cosource Medicine Technology Co LTD   (China)

Author keywords

Drug resistance; EGFR; EGFRT790M; Kinase inhibitors; NSCLC

Indexed keywords

CHMFL EGFR 26; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MUTANT PROTEIN; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

A-549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CHL CELL LINE; CHO CELL LINE; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG PROTEIN BINDING; DRUG SELECTIVITY; H1355 CELL LINE; H1703 CELL LINE; H1975 CELL LINE; H2122 CELL LINE; H3255 CELL LINE; HCC827 CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MOUSE; MOUSE MODEL; NON SMALL CELL LUNG CANCER; NONHUMAN; PC 9 CELL LINE; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY; ANIMAL; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CRICETULUS; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENETICS; LUNG TUMOR; MOLECULAR MODEL; MUTATION; NUDE MOUSE;

A549 CELLS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; ERBB RECEPTORS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MODELS, MOLECULAR; MUTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85015157883     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15443     Document Type: Article

References (32)

1. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001; 8:11-31.
2. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010; 10:760-774.
3. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24:2371-2376.
4. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105:2070-2075.
5. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008; 27:4702-4711.
6. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012; 83:407-421.
7. Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL, Denny WA. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline-and 4-(phenylamino) pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000; 43:1380-1397.
8. Yap TA, Popat S. Toward precision medicine with nextgeneration EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med. 2014; 7:285-295.
9. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4:1046-1061.
10. Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790Mmediated resistance in NSCLC. Cancer Discov. 2013; 3:1404-1415.
11. Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, Zhao P, et al. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget. 2015; 6:31313-31322. doi: 10.18632/oncotarget.5182.
12. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014; 106.
13. Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z. Discovery of a series of 2, 5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014; 57:5112-5128.
14. Ford MC, Ho PS. Computational Tools To Model Halogen Bonds in Medicinal Chemistry. J Med Chem. 2016; 59:1655-1670.
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
16. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Janne PA. Novel mutantselective EGFR kinase inhibitors against EGFR T790M. Nature. 2009; 462:1070-1074.
17. Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016; 9:34.
18. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007; 11:217-227.
19. Goldman JW, Mendenhall MA, Rettinger SR. Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. Oncologist. 2016.
20. Villadolid J, Ersek JL, Fong MK, Sirianno L, Story ES. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl Lung Cancer Res. 2015; 4:576-583.
21. Andrew D. Simmons SJ-T, Henry J. Haringsma, Andrew Allen, Thomas C. Harding. Abstract 793: Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models. Cancer Research. 2015; 75:793-793.
22. Wang A, Yan XE, Wu H, Wang W, Hu C, Chen C, Zhao Z, Zhao P, Li X, Wang L, Wang B, Ye Z, Wang J, et al. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget. 2016; 7:69760-69769. doi: 10.18632/oncotarget.11951.
23. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005; 11:8288-8294.
24. Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogeneaddicted cancer cells. Cancer Cell. 2014; 26:207-221.
25. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264:1415-1421.
26. Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony-Servat C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Gervais R, Massuti B, Moran T, Majem M, et al. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant nonsmall-cell lung cancer. Sci Rep. 2015; 5:17499.
27. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta crystallographica Section D, Biological crystallography. 2006; 62:859-866.
28. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. Journal of applied crystallography. 2007; 40:658-674.
29. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006; 125:1137-1149.
30. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60:2126-2132.
31. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010; 66:213-221.
32. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr. 2004; 60:1355-1363.